Skip to main content
. Author manuscript; available in PMC: 2018 Mar 29.
Published in final edited form as: J Hepatol. 2017 May 26;67(4):716–726. doi: 10.1016/j.jhep.2017.05.021

Fig. 2. P2X7 receptor blockade decreases LPS-mediated NF-κB activation and cytokine production in WT and CD39−/− BMDM.

Fig. 2

(A) MyD88 and p-NF-κB protein expression (B) IL-1β, (C) IL-6, and (D) IL-10 production in WT and CD39−/− LPS-primed BMDM stimulated with ATP (500 μM) or BzATP (100 μM). For P2X7 receptor inhibition, samples were pretreated with the P2X7 receptor antagonists oATP (300 μM, for 2 h) or A740003 (0.1 μM, for 30 min) or with imipramine (IMI, 30 μM for 30 min) before priming. Data are expressed as mean ± SEM of three independent experiments analyzed by one-way ANOVA, Turkey tests. Asterisks represent statistically significant differences (p <0.05; *) when comparing WT to CD39−/− or groups. Number signs (#) represent statistically significant differences (p <0.05) when the group pretreated with antagonists were compared to the same stimulated group non-pretreated.